Wall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first

Read full story on CNBC Markets
Share
Wall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first
AI disclosure

Summary

Global biotech firms are increasingly being drawn to Hong Kong for its growing investor base and proximity to Chinese pharmaceutical partners.

Original reporting

Open original source

Related coverage

Read full article on CNBC Markets

Get the AFBytes Brief

Major stories, AI-assisted analysis, and what to watch next. Free, monthly, unsubscribe anytime.